Literature DB >> 22720221

Infiltrating CTLs are bothered by HLA-E on tumors.

Marloes J M Gooden1, Thorbald van Hall.   

Abstract

We recently described the upregulation of HLA-E in ovarian and cervical cancers. Instead of interacting with natural killer cells, HLA-E appeared to inhibit intratumoral cytotoxic T lymphocytes (CTL) via the receptor CD94/NKG2A. Strikingly, the survival benefit of intraepithelial infiltrating CTL was lost in those cancers with high HLA-E expression.

Entities:  

Year:  2012        PMID： 22720221      PMCID： PMC3376958          DOI： 10.4161/onci.1.1.17961

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity.

Authors:  L C Sullivan; C S Clements; J Rossjohn; A G Brooks
Journal:  Tissue Antigens       Date:  2008-11

2.  HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.

Authors:  Marloes Gooden; Margit Lampen; Ekaterina S Jordanova; Ninke Leffers; J Baptist Trimbos; Sjoerd H van der Burg; Hans Nijman; Thorbald van Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

3.  Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.

Authors:  Bor-Ching Sheu; Shin-Heng Chiou; Ho-Hsiung Lin; Song-Nan Chow; Su-Cheng Huang; Hong-Nerng Ho; Su-Ming Hsu
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

4.  IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Authors:  Karl-Johan Malmberg; Victor Levitsky; Håkan Norell; Cristina Teixeira de Matos; Mattias Carlsten; Kjell Schedvins; Hodjattallah Rabbani; Alessandro Moretta; Kalle Söderström; Jelena Levitskaya; Rolf Kiessling
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 5.  Harnessing the immune response to treat cancer.

Authors:  H J Steer; R A Lake; A K Nowak; B W S Robinson
Journal:  Oncogene       Date:  2010-09-20       Impact factor: 9.867

6.  Expression of NK cell receptors on decidual T cells in human pregnancy.

Authors:  Tamara Tilburgs; Barbara J van der Mast; Nicole M A Nagtzaam; Dave L Roelen; Sicco A Scherjon; Frans H J Claas
Journal:  J Reprod Immunol       Date:  2009-04-25       Impact factor: 4.054

7.  Cutting edge: engagement of NKG2A on CD8+ effector T cells limits immunopathology in influenza pneumonia.

Authors:  Jing Zhou; Mitsuo Matsuoka; Harvey Cantor; Robert Homer; Richard I Enelow
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

8.  Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

Authors:  Ninke Leffers; Marloes J M Gooden; Renske A de Jong; Baukje-Nynke Hoogeboom; Klaske A ten Hoor; Harry Hollema; H Marieke Boezen; Ate G J van der Zee; Toos Daemen; Hans W Nijman
Journal:  Cancer Immunol Immunother       Date:  2008-09-13       Impact factor: 6.968

Review 9.  Cancer immunotherapy: the past, the present and the future.

Authors:  Christopher R Parish
Journal:  Immunol Cell Biol       Date:  2003-04       Impact factor: 5.126

Review 10.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.

Authors:  Francesco Colotta; Paola Allavena; Antonio Sica; Cecilia Garlanda; Alberto Mantovani
Journal:  Carcinogenesis       Date:  2009-05-25       Impact factor: 4.944
  10 in total
  8 in total

1.  Chromatin states modify network motifs contributing to cell-specific functions.

Authors:  Hongying Zhao; Tingting Liu; Ling Liu; Guanxiong Zhang; Lin Pang; Fulong Yu; Huihui Fan; Yanyan Ping; Li Wang; Chaohan Xu; Yun Xiao; Xia Li
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

2.  Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer.

Authors:  Hui Zheng; Renquan Lu; Suhong Xie; Xuemei Wen; Hongling Wang; Xiang Gao; Lin Guo
Journal:  Cancer Sci       Date:  2015-04-13       Impact factor: 6.716

3.  circCELSR1 facilitates ovarian cancer proliferation and metastasis by sponging miR-598 to activate BRD4 signals.

Authors:  Xiang-Yang Zeng; Jing Yuan; Chen Wang; Da Zeng; Jia-Hui Yong; Xiao-Yan Jiang; Hua Lan; Song-Shu Xiao
Journal:  Mol Med       Date:  2020-07-08       Impact factor: 6.354

4.  Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.

Authors:  Jean-David Fumet; Emilie Lardenois; Isabelle Ray-Coquard; Philipp Harter; Florence Joly; Ulrich Canzler; Caroline Truntzer; Olivier Tredan; Clemens Liebrich; Alain Lortholary; Daniel Pissaloux; Alexandra Leary; Jacobus Pfisterer; Alexandre Eeckhoutte; Felix Hilpert; Michel Fabbro; Christophe Caux; Jérôme Alexandre; Aurélie Houlier; Jalid Sehouli; Emilie Sohier; Rainer Kimmig; Bertrand Dubois; Dominique Spaeth; Isabelle Treilleux; Jean-Sébastien Frenel; Uwe Herwig; Olivia Le Saux; Nathalie Bendriss-Vermare; Andreas du Bois
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

Review 5.  The role of cellular proteostasis in antitumor immunity.

Authors:  Rebecca Mercier; Paul LaPointe
Journal:  J Biol Chem       Date:  2022-04-11       Impact factor: 5.486

Review 6.  The emerging role of γδ T cells in cancer immunotherapy.

Authors:  Oliver Nussbaumer; Michael Koslowski
Journal:  Immunooncol Technol       Date:  2019-06-26

Review 7.  Therapeutic targets and new directions for antibodies developed for ovarian cancer.

Authors:  Heather J Bax; Debra H Josephs; Giulia Pellizzari; James F Spicer; Ana Montes; Sophia N Karagiannis
Journal:  MAbs       Date:  2016-08-05       Impact factor: 5.857

8.  Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment.

Authors:  Yanwen Zhang; Shuwen Yu; Yali Han; Yunshan Wang; Yuping Sun
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.